In particular, the dual PI3K/mTOR inhibitor, LY3023414 (samotolisib), also reported to inhibit DNA-PK, is under investigation in number of Phase I and II trials as a monotherapy in patients with endometrial cancer (NCT02549989), and in combination with chemotherapy or other agents in patients with other solid malignancies, e.g., TNBC trial with prexasertib (NCT04032080), metastatic breast cancer with combination therapies (NCT02057133), and prostate cancer with enzalutamide (NCT02407054)[52,133,134]. This evidence concerns the gene PIK3CD and prostate cancer.